MedTrace Logo

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

NCT05844527 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-08

No results posted yet for this study

Summary

Surgical excisions are one of the most frequent cutaneous wounds. This study will compare the safety and preliminary efficacy of a novel fixed-dose combination drug MRG-001 in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing elective abdominoplasty.

Conditions

  • Wound of Skin
  • Abdominal Wound

Interventions

DRUG

MRG-001

MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.

DRUG

Saline

Sterile saline will serve as placebo treatment.

Sponsors & Collaborators

  • MedRegen LLC

    lead INDUSTRY

Principal Investigators

  • Robert D Galiano, MD FACS · Northwestern University Feinberg School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-20
Primary Completion
2024-09-01
Completion
2024-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05844527 on ClinicalTrials.gov